TGF-β/BMP signaling in skeletal biology: molecular mechanisms, regulatory networks, and therapeutic implications in development, regeneration, and disease
Liao J., Wu T., Zhang Q., Shen P., Huang Z., Wang J.
Narrative Review, published in Bone Res (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Bone Res (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41530114
- PMCID
- PMC12800155
- DOI
- 10.1038/s41413-025-00497-y
- Citations
- 9
Abstract (original English)
The transforming growth factor-β (TGF-β) and bone morphogenetic protein (BMP) signaling pathways are pivotal regulators of cellular processes, playing indispensable roles in embryogenesis, postnatal development, and tissue homeostasis. These pathways are particularly critical within the skeletal system, as they coordinate osteogenesis, chondrogenesis, and bone remodeling through intricate molecular mechanisms. TGF-β/BMP signaling is primarily transduced via canonical Smad-dependent pathways (e.g., ligands, receptors, and intracellular Smads) and the non-canonical Smad-independent (e.g., p38 mitogen-activated protein kinase, MAPK) cascade. Both pathways converge on master transcriptional regulators, including Runx2 and Osterix, and their precise coordination is indispensable for skeletal development, maintenance, and repair. The dysregulation of TGF-β/BMP signaling contributes to a spectrum of skeletal dysplasia and bone pathologies. Advances in molecular genetics, particularly gene-targeting strategies and transgenic mouse models, have deepened our understanding of the spatiotemporal control of TGF-β/BMP signaling in bone and cartilage development. Moreover, emerging research underscores extensive crosstalk between TGF-β/BMP and other critical pathways, such as Wnt/β-catenin, mitogen-activated protein kinase (MAPK), parathyroid hormone (PTH)/PTH-related protein (PTHrP), fibrobl
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.